Best Medication for Gastric Ulcers
Proton pump inhibitors (PPIs), specifically omeprazole 20-40 mg daily or lansoprazole 30 mg daily, remain the first-line treatment for gastric ulcers, with healing rates of 80-100% within 4-8 weeks. 1
Treatment Algorithm
Step 1: Determine Ulcer Etiology and Initial Treatment
For H. pylori-positive gastric ulcers:
- Use vonoprazan-based triple therapy (vonoprazan + 2 antibiotics) for H. pylori eradication as first-line treatment 2, 3
- Alternative: PPI-based triple therapy if vonoprazan unavailable
- Eradication reduces recurrence from 50-60% to 0-2% 4
For NSAID-induced gastric ulcers:
- Discontinue NSAID if possible (heals 95% of ulcers) 4
- If NSAID cannot be stopped: Use PPI (omeprazole 20-40 mg or lansoprazole 30 mg daily) for 8 weeks 5, 6
- PPIs are superior to H2-blockers for healing NSAID ulcers when the drug must be continued 5
For idiopathic gastric ulcers (H. pylori-negative, no NSAID use):
Step 2: Consider Potassium-Competitive Acid Blockers (P-CABs)
P-CABs (vonoprazan, tegoprazan) should NOT be used as first-line therapy for uncomplicated gastric ulcers due to higher costs and limited availability, despite demonstrating noninferiority to PPIs (94-96% healing rates). 1
Reserve P-CABs for:
- PPI treatment failures 1
- H. pylori eradication regimens (where they show superiority) 1
- Maintenance therapy for severe erosive esophagitis with ulcers 1
Step 3: Duration and Monitoring
- Gastric ulcers: 8 weeks of PPI therapy (4 weeks may suffice for smaller ulcers <2 cm) 4
- Post-treatment: Confirm healing endoscopically, especially for gastric ulcers to rule out malignancy
- H. pylori: Perform test-of-cure after eradication therapy 3
Comparative Efficacy
The evidence hierarchy for gastric ulcer healing:
- Omeprazole (gold standard): Meta-analysis shows omeprazole is more effective than H2-blockers with OR 2.00 (95% CI: 1.57-2.55) at 4 weeks 7
- Other PPIs (lansoprazole, pantoprazole): Comparable efficacy to omeprazole 5, 6
- H2-blockers (ranitidine, famotidine): Less effective than PPIs; OR vs placebo 2.67-3.94, but inferior to omeprazole 7
- Sucralfate/bismuth: Comparable to H2-blockers but inferior to PPIs 7
Critical Caveats
- Ulcer etiology matters: Vonoprazan shows better healing for H. pylori-associated ulcers compared to idiopathic or NSAID-related ulcers 1
- Exclude malignancy: Always biopsy gastric ulcers to rule out cancer, as acid suppression can mask malignant ulcers 1
- Refractory ulcers: If ulcers fail to heal with PPIs, consider non-acid causes (cancer, opportunistic infections, vasculitis, ischemia) before escalating to P-CABs 1
- Cost considerations: P-CABs cost significantly more than generic PPIs in the US, making them inappropriate for routine first-line use 1
Prevention of Recurrence
For patients requiring continued NSAID/aspirin therapy: